UA68336C2 - Vaccine composition for prevention or treatment of malaria - Google Patents

Vaccine composition for prevention or treatment of malaria Download PDF

Info

Publication number: UA68336C2
Authority: UA; Ukraine
Prior art keywords: malaria; composition according; protein; adjuvant; fragments
Prior art date: 1996-08-02

Application number

UA99010527A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Smithkline Beecham Biolog C A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-02

Filing date

1997-07-31

Publication date

2004-08-16

1997-07-31 Application filed by Smithkline Beecham Biolog C A filed Critical Smithkline Beecham Biolog C A

2004-08-16 Publication of UA68336C2 publication Critical patent/UA68336C2/uk

Links

239000000203 mixture Substances 0.000 title claims abstract description 23
229960005486 vaccine Drugs 0.000 title claims abstract description 23
201000004792 malaria Diseases 0.000 title claims abstract description 17
230000002265 prevention Effects 0.000 title claims abstract description 5
239000000427 antigen Substances 0.000 claims abstract description 14
102000036639 antigens Human genes 0.000 claims abstract description 14
108091007433 antigens Proteins 0.000 claims abstract description 14
239000002671 adjuvant Substances 0.000 claims abstract description 11
230000036755 cellular response Effects 0.000 claims abstract 2
108090000623 proteins and genes Proteins 0.000 claims description 40
102000004169 proteins and genes Human genes 0.000 claims description 36
230000002163 immunogen Effects 0.000 claims description 16
239000012634 fragment Substances 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 8
241000700721 Hepatitis B virus Species 0.000 claims description 5
210000004899 c-terminal region Anatomy 0.000 claims description 5
238000000034 method Methods 0.000 claims description 4
239000002569 water oil cream Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 3
230000000078 anti-malarial effect Effects 0.000 claims 2
239000003430 antimalarial agent Substances 0.000 claims 2
101100400624 Caenorhabditis elegans mbr-1 gene Proteins 0.000 claims 1
229940079593 drug Drugs 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
235000018102 proteins Nutrition 0.000 description 32
150000001413 amino acids Chemical group 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 10
229940024606 amino acid Drugs 0.000 description 10
239000000839 emulsion Substances 0.000 description 9
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
239000002245 particle Substances 0.000 description 7
210000003046 sporozoite Anatomy 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 6
101710117490 Circumsporozoite protein Proteins 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
229940087168 alpha tocopherol Drugs 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000004044 response Effects 0.000 description 4
229960000984 tocofersolan Drugs 0.000 description 4
239000002076 α-tocopherol Substances 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
101100153505 Caenorhabditis elegans tni-1 gene Proteins 0.000 description 3
241000255925 Diptera Species 0.000 description 3
241000224016 Plasmodium Species 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
235000004835 α-tocopherol Nutrition 0.000 description 3
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
239000004365 Protease Substances 0.000 description 2
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
238000010367 cloning Methods 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
210000003936 merozoite Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
239000011732 tocopherol Substances 0.000 description 2
229930003799 tocopherol Natural products 0.000 description 2
235000010384 tocopherol Nutrition 0.000 description 2
229960001295 tocopherol Drugs 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
244000298715 Actinidia chinensis Species 0.000 description 1
235000009434 Actinidia chinensis Nutrition 0.000 description 1
235000009436 Actinidia deliciosa Nutrition 0.000 description 1
101710145634 Antigen 1 Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
101710117545 C protein Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
240000002989 Euphorbia neriifolia Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
102400000368 Surface protein Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102100040396 Transcobalamin-1 Human genes 0.000 description 1
101710124861 Transcobalamin-1 Proteins 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000973 gametocyte Anatomy 0.000 description 1
230000005182 global health Effects 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229940124735 malaria vaccine Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
239000013642 negative control Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000036647 reaction Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000012770 revaccination Methods 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000001000 thyrotroph Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Immunology (AREA)
Mycology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA99010527A 1996-08-02 1997-07-31 Vaccine composition for prevention or treatment of malaria UA68336C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9616351.4A GB9616351D0 (en)	1996-08-02	1996-08-02	Vaccine composition
PCT/EP1997/004326 WO1998005355A1 (en)	1996-08-02	1997-07-31	Vaccine composition against malaria

Publications (1)

Publication Number	Publication Date
UA68336C2 true UA68336C2 (en)	2004-08-16

Family

ID=10797980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA99010527A UA68336C2 (en)	1996-08-02	1997-07-31	Vaccine composition for prevention or treatment of malaria

Country Status (32)

Country	Link
US (2)	US20020172692A1 (ru)
EP (2)	EP1623720A3 (ru)
JP (1)	JP2000517295A (ru)
KR (1)	KR20000029747A (ru)
CN (1)	CN1241639C (ru)
AP (1)	AP1166A (ru)
AR (1)	AR008799A1 (ru)
AT (1)	ATE394119T1 (ru)
AU (1)	AU706303B2 (ru)
BG (1)	BG63290B1 (ru)
BR (1)	BR9710913A (ru)
CA (1)	CA2262402A1 (ru)
CO (1)	CO4650186A1 (ru)
CZ (1)	CZ290826B6 (ru)
DE (1)	DE69738672D1 (ru)
DZ (1)	DZ2283A1 (ru)
EA (1)	EA002167B1 (ru)
GB (1)	GB9616351D0 (ru)
ID (1)	ID17860A (ru)
IL (1)	IL128318A (ru)
MA (1)	MA24291A1 (ru)
MY (1)	MY116128A (ru)
NO (1)	NO319844B1 (ru)
OA (1)	OA10969A (ru)
PE (1)	PE97298A1 (ru)
PL (1)	PL188741B1 (ru)
SK (1)	SK282438B6 (ru)
TR (1)	TR199900195T2 (ru)
UA (1)	UA68336C2 (ru)
UY (1)	UY24654A1 (ru)
WO (1)	WO1998005355A1 (ru)
ZA (1)	ZA976815B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
CA2502268A1 (en)	2002-10-23	2004-05-06	Glaxosmithkline Biologicals S.A.	Methods for vaccinating against malaria
CN102030818B (zh) *	2003-12-01	2013-03-27	株式会社明治	血管紧张素转化酶抑制肽
GB0513421D0 (en) *	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
NZ565512A (en) *	2005-08-02	2011-08-26	Novartis Vaccines & Diagnostic	Reducing interference between oil-containing adjuvants and surfactant-containing antigens
AU2007276219B2 (en) *	2006-07-18	2013-10-03	Glaxosmithkline Biologicals S.A.	Vaccines for malaria
GB0614254D0 (en) *	2006-07-18	2006-08-30	Smithkline Beecham Biolog	Vaccine
CN103585624A (zh)	2006-09-07	2014-02-19	葛兰素史密丝克莱恩生物有限公司	疫苗
UY31285A1 (es)	2007-08-13	2009-03-31		Vacunas
CN102026657A (zh) *	2007-12-21	2011-04-20	葛兰素史密丝克莱恩生物有限公司	疟疾疫苗
WO2009080803A1 (en)	2007-12-24	2009-07-02	Glaxosmithkline Biologicals S.A.	Vaccines for malaria
US20120015000A1 (en) *	2008-06-30	2012-01-19	David Lanar	Malaria vaccine of self-assembling polypeptide nanoparticles
EP3351266A1 (en) *	2009-11-05	2018-07-25	The United States of America as represented by the Secretary of the Navy	Plasmodium falciparum sporozoite and liver stage antigens
WO2012041669A1 (en)	2010-09-27	2012-04-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
GB201116248D0 (en)	2011-09-20	2011-11-02	Glaxosmithkline Biolog Sa	Liposome production using isopropanol
US20130122038A1 (en)	2011-11-14	2013-05-16	The United States Of America As Represented By The Secretary Of The Department	Heterologous prime-boost immunization using measles virus-based vaccines
US9169304B2 (en)	2012-05-01	2015-10-27	Pfenex Inc.	Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
CN104338129B (zh) *	2013-07-26	2017-05-24	中国科学院上海巴斯德研究所	雷帕霉素作为疫苗佐剂的用途及制备方法
JP7136777B2 (ja)	2016-12-07	2022-09-13	グラクソスミスクラインバイオロジカルズソシエテアノニム	新規プロセス
GB201621686D0 (en)	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
FR3066920A1 (fr)	2017-05-30	2018-12-07	Glaxosmithkline Biologicals S.A.	Nouveaux procedes de fabrication d'un adjuvant
MX2020005481A (es)	2017-12-01	2020-12-07	Glaxosmithkline Biologicals Sa	Purificacion de saponina.
WO2020245207A1 (en)	2019-06-05	2020-12-10	Glaxosmithkline Biologicals Sa	Saponin purification

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3280028D1 (en) *	1981-05-21	1989-12-28	Wellcome Found	Protozoal antigen
PT82282B (pt) *	1985-03-28	1988-02-17	Univ New York	Processo de preparacao de um conjugado de proteina de suporte-antigeno imunogenico para uso como vacina contra malaria
GB8819209D0 (en) *	1988-08-12	1988-09-14	Research Corp Ltd	Polypeptide & dna encoding same
GB9012580D0 (en) *	1990-06-06	1990-07-25	Univ Nijmegen	Novel protein
FR2679776A1 (fr) *	1991-07-31	1993-02-05	Pasteur Institut	Melange de constituants peptidiques ayant des proprietes vaccinantes contre le paludisme, notamment du a plasmodium falciparum.
JP3954643B2 (ja) *	1991-11-16	2007-08-08	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
US6169171B1 (en) *	1992-02-27	2001-01-02	Smithkline Beecham Biologicals (S.A.)	Hybrid protein between CS from plasmodium and HBSAG
EP0761231B1 (en) *	1992-06-25	2000-01-12	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Vaccine composition containing adjuvants
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
AUPM368994A0 (en) *	1994-02-04	1994-02-24	Saramane Pty Ltd	Malaria merozoite antigen subunit vaccine
FR2744723A1 (fr) *	1996-02-14	1997-08-14	Pasteur Institut	Proteine recombinante contenant un fragment c-terminal d'une proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques
FR2744724B1 (fr) *	1996-02-14	2002-08-02	Pasteur Institut	Proteine recombinante contenant un fragment c-terminal de la proteine msp-1 d'un plasmodium infectieux pour l'homme pour la production de vaccins anti-paludiques

1996
- 1996-08-02 GB GBGB9616351.4A patent/GB9616351D0/en active Pending
1997
- 1997-07-30 DZ DZ970133A patent/DZ2283A1/fr active
- 1997-07-31 ZA ZA9706815A patent/ZA976815B/xx unknown
- 1997-07-31 SK SK115-99A patent/SK282438B6/sk unknown
- 1997-07-31 MA MA24749A patent/MA24291A1/fr unknown
- 1997-07-31 UA UA99010527A patent/UA68336C2/uk unknown
- 1997-07-31 BR BR9710913A patent/BR9710913A/pt not_active Application Discontinuation
- 1997-07-31 AP APAP/P/1999/001448A patent/AP1166A/en active
- 1997-07-31 EP EP05077131A patent/EP1623720A3/en not_active Withdrawn
- 1997-07-31 CA CA002262402A patent/CA2262402A1/en not_active Abandoned
- 1997-07-31 EA EA199900069A patent/EA002167B1/ru not_active IP Right Cessation
- 1997-07-31 TR TR1999/00195T patent/TR199900195T2/xx unknown
- 1997-07-31 DE DE69738672T patent/DE69738672D1/de not_active Expired - Fee Related
- 1997-07-31 KR KR1019997000855A patent/KR20000029747A/ko not_active Application Discontinuation
- 1997-07-31 CZ CZ1999292A patent/CZ290826B6/cs not_active IP Right Cessation
- 1997-07-31 IL IL12831897A patent/IL128318A/en not_active IP Right Cessation
- 1997-07-31 MY MYPI97003495A patent/MY116128A/en unknown
- 1997-07-31 PL PL97331424A patent/PL188741B1/pl not_active IP Right Cessation
- 1997-07-31 EP EP97940062A patent/EP0957933B1/en not_active Expired - Lifetime
- 1997-07-31 ID IDP972672A patent/ID17860A/id unknown
- 1997-07-31 JP JP10507631A patent/JP2000517295A/ja active Pending
- 1997-07-31 AU AU42040/97A patent/AU706303B2/en not_active Ceased
- 1997-07-31 WO PCT/EP1997/004326 patent/WO1998005355A1/en active IP Right Grant
- 1997-07-31 AT AT97940062T patent/ATE394119T1/de not_active IP Right Cessation
- 1997-07-31 CN CNB971983607A patent/CN1241639C/zh not_active Expired - Fee Related
- 1997-08-01 AR ARP970103502A patent/AR008799A1/es not_active Application Discontinuation
- 1997-08-01 UY UY24654A patent/UY24654A1/es not_active IP Right Cessation
- 1997-08-01 CO CO97044242A patent/CO4650186A1/es unknown
- 1997-08-01 PE PE1997000672A patent/PE97298A1/es not_active Application Discontinuation
1999
- 1999-02-01 NO NO19990464A patent/NO319844B1/no unknown
- 1999-02-02 BG BG103141A patent/BG63290B1/bg unknown
- 1999-02-02 OA OA9900022A patent/OA10969A/en unknown
2001
- 2001-12-18 US US10/024,860 patent/US20020172692A1/en not_active Abandoned
2006
- 2006-08-11 US US11/463,933 patent/US20060292170A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20020172692A1 (en)	2002-11-21
CZ290826B6 (cs)	2002-10-16
MY116128A (en)	2003-11-28
CO4650186A1 (es)	1998-09-03
JP2000517295A (ja)	2000-12-26
ID17860A (id)	1998-01-29
PL188741B1 (pl)	2005-04-29
EP1623720A3 (en)	2006-02-22
AU706303B2 (en)	1999-06-10
ATE394119T1 (de)	2008-05-15
EP0957933A1 (en)	1999-11-24
MA24291A1 (fr)	1998-04-01
EA199900069A1 (ru)	1999-10-28
UY24654A1 (es)	2001-08-27
AU4204097A (en)	1998-02-25
NO990464L (no)	1999-02-01
NO319844B1 (no)	2005-09-19
WO1998005355A1 (en)	1998-02-12
EP1623720A2 (en)	2006-02-08
EA002167B1 (ru)	2002-02-28
KR20000029747A (ko)	2000-05-25
SK282438B6 (sk)	2002-02-05
ZA976815B (en)	1998-05-11
CN1241639C (zh)	2006-02-15
BR9710913A (pt)	1999-08-17
SK11599A3 (en)	2000-03-13
AR008799A1 (es)	2000-02-23
EP0957933B1 (en)	2008-05-07
GB9616351D0 (en)	1996-09-11
NO990464D0 (no)	1999-02-01
CA2262402A1 (en)	1998-02-12
IL128318A0 (en)	2000-01-31
AP9901448A0 (en)	1999-03-31
PL331424A1 (en)	1999-07-19
AP1166A (en)	2003-06-30
CN1231613A (zh)	1999-10-13
BG63290B1 (bg)	2001-09-28
BG103141A (en)	1999-08-31
DZ2283A1 (fr)	2002-12-25
IL128318A (en)	2002-04-21
CZ29299A3 (cs)	1999-06-16
US20060292170A1 (en)	2006-12-28
PE97298A1 (es)	1999-02-14
TR199900195T2 (xx)	1999-04-21
OA10969A (en)	2003-03-04
DE69738672D1 (de)	2008-06-19

Publication	Publication Date	Title
UA68336C2 (en)	2004-08-16	Vaccine composition for prevention or treatment of malaria
JP4126079B2 (ja)	2008-07-30	アジュバント組成物
US20070196394A1 (en)	2007-08-23	Immunogenic compositions comprising Liver Stage Malarial Antigens
AU2016201589B2 (en)	2016-11-24	Peptide adjuvants
US20060073171A1 (en)	2006-04-06	Vaccine composition against malaria
EP0241725B1 (en)	1992-12-09	Improvements in and relating to vaccines
US20110262469A1 (en)	2011-10-27	Malaria vaccine based on fragments and combination of fragments of the cs protein of plasmodium vivax
KR0173365B1 (ko)	1999-02-01	C형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀